HAYWARD, Calif.--(BUSINESS WIRE)--
Impax Laboratories, Inc. (NASDAQ: IPXL) (the “Company”)
today announced that Arthur A. Koch, the Company’s Executive Vice
President, Finance, and Chief Financial Officer, has informed the
Company of his decision to resign from his position with the Company to
pursue other opportunities. Mr. Koch will assist the Company to help
ensure a smooth transition.
The Company also announced that Bryan M. Reasons, who currently serves
as Vice President, Finance, has been appointed as Acting Chief Financial
Officer and that the Company will initiate a search for a permanent
successor.
“During the past seven years that Arthur Koch has been with us, the
Company has grown tremendously, and I deeply appreciate his service to
the Company,” said Larry Hsu, president and CEO of Impax Laboratories.
“Bryan Reasons is an able and experienced financial executive who will
be the interim CFO reporting to me as we conduct an external search for
a permanent CFO.”
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical
company applying its formulation expertise and drug delivery technology
to the development of controlled-release and specialty generics in
addition to the development of branded products. Impax markets its
generic products through its Global Pharmaceuticals division and markets
its branded products through the Impax Pharmaceuticals division.
Additionally, where strategically appropriate, Impax has developed
marketing partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a full
range of capabilities in its Hayward, Philadelphia and Taiwan
facilities. For more information, please visit the Company's Web site
at: www.impaxlabs.com.
Source: Impax Laboratories, Inc.